Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/cmdc.202000921 http://scihub22266oqcxt.onion/10.1002/cmdc.202000921 33348462!8248156!33348462     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       ChemMedChem 2021 ; 16 (9): 1425-1426 Nephropedia Template TP {{tp|p=33348462|t=2021. Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease |pdf=|usr=}}{{33348462}} gab.com Text Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease JO: ChemMedChem http://www.kidney.de/pget.php?&tw=1&pmid=33348462 #FOAvip In a recent publication, Eleftheriou et al. proposed that inhibitors of dipeptidyl peptidase-4 (DPP-4) are functional inhibitors of the main protease (M(pro) ) of SARS-CoV-2. Their predictions prompted the authors to suggest linagliptin, a DPP-4 inhibitor and approved anti-diabetes drug, as a repurposed drug candidate against the ongoing COVID-19 pandemic. We used an enzymatic assay measuring the inhibition of M(pro) catalytic activity in the presence of four different commercially available gliptins (linagliptin, sitagliptin, alogliptin and saxagliptin) and several structural analogues of linagliptin to study the binding of DPP-4 inhibitors to M(pro) and their functional activity. We show here that DPP-4 inhibitors like linagliptin, other gliptins and structural analogues are inactive against M(pro) . Twit Text FOAVip Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease ????ChemMedChem http://www.kidney.de/pget.php?&tw=1&pmid=33348462 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33348462 #FOAvip English Wikipedia <ref>{{Cite pmid|33348462}}</ref> Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease #MMPMID33348462 Nar H; Schnapp G; Hucke O; Hardman TC; Klein T ChemMedChem 2021[May]; 16 (9): 1425-1426 PMID33348462show ga In a recent publication, Eleftheriou et al. proposed that inhibitors of dipeptidyl peptidase-4 (DPP-4) are functional inhibitors of the main protease (M(pro) ) of SARS-CoV-2. Their predictions prompted the authors to suggest linagliptin, a DPP-4 inhibitor and approved anti-diabetes drug, as a repurposed drug candidate against the ongoing COVID-19 pandemic. We used an enzymatic assay measuring the inhibition of M(pro) catalytic activity in the presence of four different commercially available gliptins (linagliptin, sitagliptin, alogliptin and saxagliptin) and several structural analogues of linagliptin to study the binding of DPP-4 inhibitors to M(pro) and their functional activity. We show here that DPP-4 inhibitors like linagliptin, other gliptins and structural analogues are inactive against M(pro) . |*Drug Repositioning[MESH] |Adamantane/analogs & derivatives/chemistry[MESH] |Antiviral Agents/chemistry[MESH] |Coronavirus 3C Proteases/*antagonists & inhibitors[MESH] |Dipeptides/chemistry[MESH] |Dipeptidyl-Peptidase IV Inhibitors/*chemistry[MESH] |Enzyme Assays[MESH] |Heterocyclic Compounds/*chemistry[MESH] |Linagliptin/chemistry[MESH] |Piperidines/chemistry[MESH] |SARS-CoV-2/*enzymology[MESH] |Sitagliptin Phosphate/chemistry[MESH]Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Proteas(epmc).pdf DeepDyve Pubget Overpricing